|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.330 USD | -1.48% |
|
-3.62% | -10.74% |
| 11-14 | Marker Therapeutics Q3 net loss narrows to $2 mln | RE |
| 11-13 | Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 | CI |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash And Equivalents | 21.35M | 42.35M | 11.78M | 15.11M | 19.19M | |||||
Total Cash And Short Term Investments | 21.35M | 42.35M | 11.78M | 15.11M | 19.19M | |||||
Other Receivables | 1M | 237 | 2.4M | 1.03M | 2.35M | |||||
Total Receivables | 1M | 237 | 2.4M | 1.03M | 2.35M | |||||
Prepaid Expenses | 2.06M | 2.48M | 2.44M | 988K | 484K | |||||
Restricted Cash | - | 1.15M | - | - | - | |||||
Total Current Assets | 24.41M | 45.98M | 16.62M | 17.13M | 22.02M | |||||
Gross Property Plant And Equipment | 21.79M | 24.89M | 23.08M | - | - | |||||
Accumulated Depreciation | -591K | -2.74M | -5.27M | - | - | |||||
Net Property Plant And Equipment | 21.2M | 22.15M | 17.8M | - | - | |||||
Total Assets | 45.61M | 68.14M | 34.42M | 17.13M | 22.02M | |||||
Liabilities | ||||||||||
Accounts Payable, Total | 2.94M | 5.14M | 1.61M | 961K | 1.07M | |||||
Accrued Expenses, Total | 2.67M | 3.33M | 2.68M | 1.91M | 2.19M | |||||
Short-term Borrowings | - | - | - | - | - | |||||
Current Portion of Leases | 389K | 620K | 577K | - | - | |||||
Unearned Revenue Current, Total | - | 1.15M | 2.5M | - | - | |||||
Other Current Liabilities | 404K | 2.66M | 414K | 205K | 205K | |||||
Total Current Liabilities | 6.4M | 12.9M | 7.78M | 3.07M | 3.46M | |||||
Long-Term Leases | 11.87M | 11.25M | 7.04M | - | - | |||||
Total Liabilities | 18.27M | 24.15M | 14.82M | 3.07M | 3.46M | |||||
Common Stock, Total | 50.73K | 83.08K | 8.41K | 8.89K | 10.71K | |||||
Additional Paid In Capital | 384M | 442M | 448M | 450M | 466M | |||||
Retained Earnings | -356M | -398M | -428M | -436M | -447M | |||||
Total Common Equity | 27.34M | 43.99M | 19.6M | 14.05M | 18.56M | |||||
Total Equity | 27.34M | 43.99M | 19.6M | 14.05M | 18.56M | |||||
Total Liabilities And Equity | 45.61M | 68.14M | 34.42M | 17.13M | 22.02M | |||||
Supplemental Items | ||||||||||
ECS Total Shares Outstanding on Filing Date | 5.07M | 8.31M | 8.8M | 8.9M | 10.71M | |||||
ECS Total Common Shares Outstanding | 5.07M | 8.31M | 8.41M | 8.89M | 10.71M | |||||
Book Value / Share | 5.39 | 5.29 | 2.33 | 1.58 | 1.73 | |||||
Tangible Book Value | 27.34M | 43.99M | 19.6M | 14.05M | 18.56M | |||||
Tangible Book Value Per Share | 5.39 | 5.29 | 2.33 | 1.58 | 1.73 | |||||
Total Debt | 12.26M | 11.87M | 7.62M | 0 | 0 | |||||
Net Debt | -9.1M | -30.48M | -4.17M | -15.11M | -19.19M | |||||
Debt Equivalent Oper. Leases | 9.19M | 18.46M | 17.43M | - | - | |||||
Account Code - Inventory Valuation | 3 | 3 | 3 | 3 | 3 | |||||
Machinery, Total | 3.87M | 9.66M | 13.65M | - | - | |||||
Full Time Employees | 44 | 56 | 67 | 8 | 5 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















